Literature DB >> 30299354

How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients.

Aaron J Heffernan1,2, Fekade B Sime2, Fabio S Taccone3, Jason A Roberts2,4,5.   

Abstract

PURPOSE OF REVIEW: Optimized antibiotic dosing regimens improve survival rates in critically ill patients. However, dose optimization is challenging because of fluctuating antibiotic pharmacokinetics both between patients and within a single patient. This study reviews the pharmacokinetic changes that occur in critically ill patients, along with the pharmacodynamics and toxicodynamics of antibiotics commonly used for the treatment of Gram-negative bacterial infections to formulate a recommendation for antibiotic dosing at the bedside. RECENT
FINDINGS: Recent studies highlight that critically ill patients do not achieve therapeutic antibiotic exposures with standard antibiotic dosing. Although dose increases are required, the method of administration, such as the use of β-lactam antibiotic continuous infusions and nebulized aminoglycoside administration, may improve efficacy and limit toxicity. In addition, the increased availability of therapeutic drug monitoring and antibiotic dosing software allow the formulation of individualized dosing regimens at the bedside.
SUMMARY: When prescribing antibiotic doses, the clinician should consider antibiotic pharmacokinetic and pharmacodynamic principles. Before initiating high-dose antibiotic therapy, therapeutic drug monitoring may be considered to assist the clinician to optimize antibiotic treatment and minimize potential toxicity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30299354     DOI: 10.1097/QCO.0000000000000494

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  5 in total

1.  Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients.

Authors:  Aaron J Heffernan; Fekade B Sime; Nilesh Kumta; Steven C Wallis; Brett McWhinney; Jacobus Ungerer; Gloria Wong; Gavin M Joynt; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2022-05-16       Impact factor: 5.938

2.  Quantification of Ceftaroline in Human Plasma Using High-Performance Liquid Chromatography with Ultraviolet Detection: Application to Pharmacokinetic Studies.

Authors:  Ana Alarcia-Lacalle; Helena Barrasa; Javier Maynar; Andrés Canut-Blasco; Carmen Gómez-González; María Ángeles Solinís; Arantxazu Isla; Alicia Rodríguez-Gascón
Journal:  Pharmaceutics       Date:  2021-06-25       Impact factor: 6.321

3.  The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial.

Authors:  A Abdulla; T M J Ewoldt; N G M Hunfeld; A E Muller; W J R Rietdijk; S Polinder; T van Gelder; H Endeman; B C P Koch
Journal:  BMC Infect Dis       Date:  2020-01-17       Impact factor: 3.090

Review 4.  Antibiotics and the Nervous System-Which Face of Antibiotic Therapy Is Real, Dr. Jekyll (Neurotoxicity) or Mr. Hyde (Neuroprotection)?

Authors:  Magdalena Hurkacz; Lukasz Dobrek; Anna Wiela-Hojeńska
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

Review 5.  The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review.

Authors:  Alessandro Lazzaro; Gabriella De Girolamo; Valeria Filippi; Giuseppe Pietro Innocenti; Letizia Santinelli; Giancarlo Ceccarelli; Enrico Maria Trecarichi; Carlo Torti; Claudio Maria Mastroianni; Gabriella d'Ettorre; Alessandro Russo
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.